You are here

A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

Last updated on December 16, 2017

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
La Mesa, California, 91942 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Stroke
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-90 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Males & females age 40-90 years

Enrolled in study within 6 hours of onset of stroke symptoms

Willing to sign informed consent form

No significant disabilities prior to stroke

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Treatment with t-PA (tissue plasminogen activator)

Premorbid modified rankin scale score of 2 or more

NCT00073476
Pfizer
Terminated
A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Ischemic Stroke
NCT01208233
All Genders
18+
Years
Multiple Sites
Acute Ischemic Stroke
NCT00827190
All Genders
A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a 72-Hour Infusion of CP-101,606 in Subjects With Acute Ischemic Stroke.
The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Stroke
Drug: traxiprodil (CP-101,606)
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
300
February 2005
Not Provided

Inclusion Criteria:

Males & females age 40-90 years

Enrolled in study within 6 hours of onset of stroke symptoms

Willing to sign informed consent form

No significant disabilities prior to stroke

Exclusion Criteria:

Treatment with t-PA (tissue plasminogen activator)

Premorbid modified rankin scale score of 2 or more

Sexes Eligible for Study: All
40 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Estonia,   Germany,   Hungary,   Italy,   Portugal,   Singapore,   Spain,   United States
 
 
NCT00073476
A1611005
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2006

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now